Galli Stephen J 4

What Happened

• Stephen J. Galli, a director of Atossa Therapeutics, was granted 10,000 restricted stock units (RSUs) on May 12, 2026. The award was reported at $0.00 per share (no cash paid) and therefore has an immediate cash value of $0 on grant. This is an equity award (code A) as part of compensation, not an open-market purchase or sale.

Key Details

• Transaction date: May 12, 2026; Filing date: May 14, 2026 (filed within the standard two-business-day Form 4 window).
• Grant: 10,000 RSUs; Reported price: $0.00; Reported immediate cash value: $0.
• Shares owned following the transaction: Not disclosed in the provided filing.
• Footnote: F1 — Each RSU represents a contingent right to one share of the company’s common stock; the RSUs vest on the first anniversary of May 12, 2026 (i.e., May 12, 2027).
• Transaction code: A (award/grant).

Context

• RSUs are a deferred equity compensation—no shares are issued at grant and no cash was exchanged. At vesting the RSUs will convert to common shares (and may be subject to tax withholding or other conditions).
• Grants to directors are common as part of compensation and do not necessarily indicate immediate buying or selling sentiment in the market.